| Illumigen Biosciences, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110071073 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 03-24-2011 |
| 20100172833 | METHODS AND COMPOSITIONS FOR DIAGNOSING HEPATOCELLULAR CARCINOMA - Methods for the diagnosis of hepatocellular carcinoma (HCC) are set forth. Improved assay methods and scanning methods are included that employ non-cell-associated and cell-associated HCC related proteins. Such methods are based upon the discovery of genes that were up-regulated in diseased versus normal tissue as well as in HCC tissue when compared to the tissue of patients with other ailments. | 07-08-2010 |
| 20090291074 | MUTATIONS IN OAS1 GENES - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 11-26-2009 |
| 20090186028 | Detection of mutations in a gene associated with resistance to viral infection - A method for detecting a mutation related to the gene encoding LDLR. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human LDLR, including antisense oligonucleotides, methods, and compositions specific for human LDLR, are also provided. | 07-23-2009 |
| 20090123472 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 05-14-2009 |
